Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

× No keyword cloud information.

54 in total

1. Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients.

Authors: Seiya Saito; Naoko Hayashi; Nobutaka Sato; Masaaki Iwatsuki; Yoshifumi Baba; Yasuo Sakamoto; Yuji Miyamoto; Masayuki Watanabe; Minoru Yoshida; Kenji Sakai; Takashi Katsumori; Shigeru Katahuchi; Nobuyuki Shigaki; Kazutaka Yamada; Masami Kimura; Tomio Tanigawa; Sadamu Takano; Masafumi Kuramoto; Hideo Baba
Journal: Int J Clin Oncol Date: 2012-06-05 Impact factor: 3.402

2. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.

Authors: Seiya Sato; Hiroaki Itamochi
Journal: Ther Adv Med Oncol Date: 2014-11 Impact factor: 8.168

Review 3. Targeting angiogenesis in gynecologic cancers.

Authors: Behrouz Zand; Robert L Coleman; Anil K Sood
Journal: Hematol Oncol Clin North Am Date: 2012-06 Impact factor: 3.722

4. Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?

Authors: Susana Banerjee; Stan B Kaye
Journal: Nat Rev Clin Oncol Date: 2012-02-28 Impact factor: 66.675

Review 5. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers.

Authors: Taher Abu-Hejleh; James J Mezhir; Michael J Goodheart; Thorvardur R Halfdanarson
Journal: Curr Oncol Rep Date: 2012-08 Impact factor: 5.075

6. Recognizing the toxicity of "nontoxic" drugs employed in the management of malignant disease.

Authors: Maurie Markman
Journal: Curr Oncol Rep Date: 2007-09 Impact factor: 5.075

7. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups.

Authors: Wei-Xiang Qi; Zan Shen; Li-Na Tang; Yang Yao
Journal: Eur J Clin Pharmacol Date: 2014-05-27 Impact factor: 2.953

8. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.

Authors: Setsuko K Chambers; Mary C Clouser; Amanda F Baker; Denise J Roe; Haiyan Cui; Molly A Brewer; Kenneth D Hatch; Michael S Gordon; Mike F Janicek; Jeffrey D Isaacs; Alan N Gordon; Raymond B Nagle; Heather M Wright; Janice L Cohen; David S Alberts
Journal: Clin Cancer Res Date: 2010-11-01 Impact factor: 12.531

Review 9. Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors: Timothy A Yap; Craig P Carden; Stan B Kaye
Journal: Nat Rev Cancer Date: 2009-03 Impact factor: 60.716

10. Bowel perforation in non-small cell lung cancer after bevacizumab therapy.

Authors: Elisabeth Schellhaas; Christoph Loddenkemper; Alexander Schmittel; Heinz-J Buhr; Uwe Pohlen
Journal: Invest New Drugs Date: 2008-07-30 Impact factor: 3.850